Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M

Lung cancer in never-smokers is an important disease often characterized by mutations in EGFR, yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mTOR as a new and potentially valuable target for EGFR mutant lung cancer, as mTOR was activated...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kawabata, Shigeru, Mercado-Matos, José R., Hollander, M. Christine, Donahue, Danielle, Wilson, Willie, Regales, Lucia, Butaney, Mohit, Pao, William, Wong, Kwok-Kin, Jänne, Pasi A., Dennis, Phillip A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4110638/
https://ncbi.nlm.nih.gov/pubmed/24931608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2014.05.039
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky